Published in Gynecol Oncol on December 01, 1995
Clear cell adenocarcinoma of a female urethra: A case report and review of the literature. N Am J Med Sci (2009) 1.04
Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol (2014) 0.86
Clear cell adenocarcinoma of the urethra: review of the literature. Int J Surg Oncol (2015) 0.78
Adenocarcinoma of the urethra with mucinous features. Rev Urol (2015) 0.75
A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev (1999) 6.34
Human epithelial ovarian cancer allelotype. Cancer Res (1993) 2.08
Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol (2012) 2.01
Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 1.96
Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol (2000) 1.93
Identification of a low-risk subset of patients with stage IB invasive squamous cancer of the cervix possibly suited to less radical surgical treatment. Gynecol Oncol (1995) 1.75
Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol (1999) 1.69
Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol (1996) 1.55
Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol (1996) 1.51
Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol (2000) 1.43
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer (2011) 1.39
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res (2002) 1.31
Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol (2000) 1.30
Primary ovarian carcinoid tumors. Gynecol Oncol (1996) 1.26
Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer (2006) 1.26
Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol (2001) 1.25
Serous borderline tumor of the paratestis: a report of seven cases. Am J Surg Pathol (2001) 1.25
A method for determination of the methylated constituents of transfer ribonucleic acid. Biochemistry (1974) 1.23
Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res (1994) 1.18
Solitary fibrous tumor: a study of cytologic features of six cases diagnosed by fine-needle aspiration. Diagn Cytopathol (2001) 1.18
Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome. Gynecol Oncol (1994) 1.18
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol (1988) 1.16
Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol (1998) 1.16
Deciduoid peritoneal mesothelioma. An unusual phenotype affecting young females. Am J Surg Pathol (1994) 1.16
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer (2008) 1.14
Intracardiac leiomyomatosis: echocardiographic features. Chest (1999) 1.13
Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol (2000) 1.13
Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher's syndrome. Am J Pathol (2000) 1.12
HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol (1992) 1.11
Hematogenous dissemination in corpus cancer. Gynecol Oncol (2001) 1.10
Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol (1994) 1.10
Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol (2001) 1.08
Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. Gynecol Oncol (2001) 1.08
Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res (1993) 1.08
Stage I ovarian epithelial carcinoma: survival analysis following definitive treatment. Gynecol Oncol (1991) 1.07
Carcinoma of the vulva: analysis of treatment failures. Am J Obstet Gynecol (1982) 1.05
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. J Urol (1999) 1.00
Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (1999) 0.99
Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol (2013) 0.99
Clinicopathologic analysis of uterine malignant mixed müllerian tumors. Gynecol Oncol (1989) 0.99
CA 125 in gynecologic practice. Am J Obstet Gynecol (1986) 0.97
Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol (1989) 0.96
Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol (2007) 0.96
The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol (2000) 0.95
Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer (2007) 0.95
Renal plasmacytoma: Mayo Clinic experience and review of the literature. Urology (1991) 0.95
Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol (2013) 0.93
Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol (1983) 0.93
Benign tumors of the breast with multinucleated stromal giant cells. Immunohistochemical analysis of six cases and review of the literature. Virchows Arch (2001) 0.92
Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol (1985) 0.91
Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol (2011) 0.91
Significance of pathologic patterns of pelvic lymph node metastases in endometrial cancer. Gynecol Oncol (2001) 0.90
Peripheral nerve and ureteral tolerance to intraoperative radiation therapy: clinical and dose-response analysis. Radiother Oncol (1990) 0.89
Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol (1993) 0.88
Modified radical hysterectomy: morbidity and mortality. Gynecol Oncol (1995) 0.88
Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen. Gynecol Oncol (1994) 0.87
Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer (1990) 0.87
Uterine prolapse complicated by endometrial cancer. Am J Obstet Gynecol (1995) 0.87
Gracilis myocutaneous vaginal reconstruction. Mayo Clin Proc (1984) 0.87
Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol (2013) 0.87
Surgically treated adnexal masses in infancy, childhood, and adolescence. Am J Obstet Gynecol (1994) 0.86
Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol (2000) 0.86
Multifocal malignant melanoma arising in vesicovaginal melanosis. Arch Pathol Lab Med (1991) 0.86
A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev (2001) 0.86
Modified radical hysterectomy in the treatment of early squamous cervical cancer. Gynecol Oncol (1999) 0.85
Surgical management of desmoid tumors of the female pelvis. J Am Coll Surg (2000) 0.85
Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol (1990) 0.85
Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep (1985) 0.85
DNA ploidy in endometrial carcinoma: major objective prognostic factor. Mayo Clin Proc (1990) 0.84
Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery. Gynecol Oncol (1998) 0.84
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant (2009) 0.84
Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol (2001) 0.84
Wertheim hysterectomy in the geriatric population. Gynecol Oncol (1988) 0.83
Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. Am J Obstet Gynecol (1983) 0.83
Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecol Oncol (1989) 0.83